Literature DB >> 34985112

Cannabis in Parkinson's Disease - the patient's perspective versus clinical trials: a systematic literature review.

Monika Figura1, Dariusz Koziorowski2, Jarosław Sławek3,4.   

Abstract

Cannabis and cannabinoids are often considered in the treatment of Parkinson's Disease (PD). The purpose of this paper was to perform a systematic review of the available data on cannabis treatment. We aimed to assess randomised trials as well as surveys among patients. We identified 569 papers on PD and cannabinoid treatment. Of these, there were only seven papers featuring randomised trials on the effects of different cannabinoids on PD. The results of these trials did not support the efficacy of cannabinoids in the treatment of motor signs of PD. Based on the available data, we conclude that there is currently insufficient data to support the administration of cannabinoids to PD patients. Larger, randomised studies of cannabis use in PD should be conducted.

Entities:  

Keywords:  CBD; Parkinson’s Disease; cannabis; marijuana; non-motor symptoms

Mesh:

Substances:

Year:  2022        PMID: 34985112     DOI: 10.5603/PJNNS.a2022.0004

Source DB:  PubMed          Journal:  Neurol Neurochir Pol        ISSN: 0028-3843            Impact factor:   1.621


  2 in total

Review 1.  Randomized controlled trials on the use of cannabis-based medicines in movement disorders: a systematic review.

Authors:  P Oikonomou; W H Jost
Journal:  J Neural Transm (Vienna)       Date:  2022-07-20       Impact factor: 3.850

2.  Neurogenetic and Epigenetic Aspects of Cannabinoids.

Authors:  Catherine A Dennen; Kenneth Blum; Abdalla Bowirrat; Jag Khalsa; Panayotis K Thanos; David Baron; Rajendra D Badgaiyan; Ashim Gupta; Eric R Braverman; Mark S Gold
Journal:  Epigenomes       Date:  2022-08-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.